Treatment of ChronicMyelomonocytic Leukemia with 5-Azacytidine: Case Reports

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F12%3A33142581" target="_blank" >RIV/61989592:15110/12:33142581 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.hindawi.com/crim/hematology/2012/369086/" target="_blank" >http://www.hindawi.com/crim/hematology/2012/369086/</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1155/2012/369086" target="_blank" >10.1155/2012/369086</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Treatment of ChronicMyelomonocytic Leukemia with 5-Azacytidine: Case Reports

Popis výsledku v původním jazyce

Epigenetic therapy with hypomethylating agent (5-azacytidine; AZA) is common in the management of specific subtypes of myelodysplastic syndrome (MDS), but there are only few studies in chronic myelomonocytic leukemia (CMML) patients. In this paper our experience with 3 CMML patients treated with AZA is described. In one patient transfusion independency was observed after 4 treatment cycles; in one case a partial response was recorded, but a progression to acute myeloid leukemia (AML) after 13 AZA cycleshas appeared. In one patient, AZA in reduced dosage was administered as a bridging treatment before allogeneic stem cell transplantation (ASCT), but in the control bone marrow aspirate (before ASCT) a progression to AML was recorded. Future studies aremandatory for evaluation of new molecular and clinical features which could predict the efficiency of hypomethylating agents in CMML therapy with respect to overall survival, event-free survival, quality-adjusted life year, and pharmacoec

Název v anglickém jazyce

Treatment of ChronicMyelomonocytic Leukemia with 5-Azacytidine: Case Reports

Popis výsledku anglicky

Epigenetic therapy with hypomethylating agent (5-azacytidine; AZA) is common in the management of specific subtypes of myelodysplastic syndrome (MDS), but there are only few studies in chronic myelomonocytic leukemia (CMML) patients. In this paper our experience with 3 CMML patients treated with AZA is described. In one patient transfusion independency was observed after 4 treatment cycles; in one case a partial response was recorded, but a progression to acute myeloid leukemia (AML) after 13 AZA cycleshas appeared. In one patient, AZA in reduced dosage was administered as a bridging treatment before allogeneic stem cell transplantation (ASCT), but in the control bone marrow aspirate (before ASCT) a progression to AML was recorded. Future studies aremandatory for evaluation of new molecular and clinical features which could predict the efficiency of hypomethylating agents in CMML therapy with respect to overall survival, event-free survival, quality-adjusted life year, and pharmacoec

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT12218" target="_blank" >NT12218: Individualizovaná léčba chronických myeloproliferativních stavů a myelodysplastického syndromu - studie buněčné metabolomiky</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)<br>S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Case Reports in Hematology

ISSN

2090-6579

e-ISSN

—

Svazek periodika

2012

Číslo periodika v rámci svazku

369086

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

4

Strana od-do

1-4

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—